Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley B Cohen

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Nature Reviews. Rheumatology|January 16, 2021
JAK inhibitors and VTE risk: how concerned should we be?Stanley B Cohen
Arthritis and Rheumatism|February 1, 2011
Why the ACR?Stanley B Cohen
The Journal of Rheumatology. Supplement|May 3, 2006
Updates from B Cell Trials: EfficacyStanley B Cohen
Best Practice & Research. Clinical Rheumatology|August 25, 2010
Targeting the B cell in rheumatoid arthritisStanley B Cohen
Nature Reviews. Rheumatology|December 2, 2010
Comorbidities: glucocorticoids and osteoporosis: predicting fracture riskStanley B Cohen
Medgenmed : Medscape General Medicine|December 22, 2005
B-cell depletion for rheumatic diseases: where are we?Stanley B Cohen
The Lancet. Rheumatology|January 17, 2024
Biosimilars for rheumatic diseases: China joins the clubStanley B Cohen
Rheumatic Diseases Clinics of North America|June 3, 2004
The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritisStanley B Cohen
Current Rheumatology Reports|January 10, 2004
An update on bisphosphonatesStanley B Cohen
The Lancet. Rheumatology|January 26, 2024
Safety profile of JAK inhibitors: a focus on baricitinibStanley B Cohen
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Nature Reviews. Rheumatology|January 16, 2021
JAK inhibitors and VTE risk: how concerned should we be?Stanley B Cohen
Arthritis and Rheumatism|February 1, 2011
Why the ACR?Stanley B Cohen
The Journal of Rheumatology. Supplement|May 3, 2006
Updates from B Cell Trials: EfficacyStanley B Cohen
Best Practice & Research. Clinical Rheumatology|August 25, 2010
Targeting the B cell in rheumatoid arthritisStanley B Cohen
Nature Reviews. Rheumatology|December 2, 2010
Comorbidities: glucocorticoids and osteoporosis: predicting fracture riskStanley B Cohen
Medgenmed : Medscape General Medicine|December 22, 2005
B-cell depletion for rheumatic diseases: where are we?Stanley B Cohen
The Lancet. Rheumatology|January 17, 2024
Biosimilars for rheumatic diseases: China joins the clubStanley B Cohen
Rheumatic Diseases Clinics of North America|June 3, 2004
The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritisStanley B Cohen
Current Rheumatology Reports|January 10, 2004
An update on bisphosphonatesStanley B Cohen
The Lancet. Rheumatology|January 26, 2024
Safety profile of JAK inhibitors: a focus on baricitinibStanley B Cohen
Pageof 8